Protara Therapeutics, Inc. (NASDAQ:TARA) Stock Has Average Target Price of $26.25

Protara Therapeutics, Inc. (NASDAQ:TARA) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $26.25.

A number of brokerages have commented on TARA. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 5th.

Protara Therapeutics Trading Down 1.2%

Shares of NASDAQ TARA opened at $3.21 on Wednesday. The firm’s 50-day moving average price is $3.85 and its 200-day moving average price is $4.40. Protara Therapeutics has a 1-year low of $3.19 and a 1-year high of $7.82. The firm has a market capitalization of $189.69 million, a P/E ratio of -2.38 and a beta of 1.49.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.03). Equities research analysts forecast that Protara Therapeutics will post -1.4 EPS for the current year.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of TARA. Corient Private Wealth LP bought a new position in shares of Protara Therapeutics in the second quarter valued at $41,000. AXQ Capital LP bought a new stake in shares of Protara Therapeutics during the fourth quarter worth about $58,000. Empery Asset Management LP acquired a new stake in shares of Protara Therapeutics in the 4th quarter worth about $68,000. The Manufacturers Life Insurance Company raised its holdings in shares of Protara Therapeutics by 22.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock worth $71,000 after acquiring an additional 2,464 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in Protara Therapeutics in the 2nd quarter valued at about $69,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including certain solid tumors and lymphatic disorders.

Protara’s lead product candidate is TARA-002, an investigational cell-based therapy derived from a proprietary preparation of inactivated Streptococcus pyogenes. The company is evaluating TARA-002 in non-muscle-invasive bladder cancer and lymphatic malformations, a rare condition involving abnormal growth of lymphatic vessels.